Original language | English (US) |
---|---|
Pages (from-to) | e445 |
Journal | Journal of the American Academy of Dermatology |
Volume | 83 |
Issue number | 6 |
DOIs | |
State | Published - Dec 2020 |
ASJC Scopus subject areas
- Dermatology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Journal of the American Academy of Dermatology, Vol. 83, No. 6, 12.2020, p. e445.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - In response to
T2 - “Reply to research letter”
AU - Wan, Marilyn T.
AU - Shin, Daniel B.
AU - Winthrop, Kevin L.
AU - Gelfand, Joel M.
N1 - Funding Information: Funding sources: Supported in part by a grant (P30-AR-069589-03) from the National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases to Dr Gelfand.Conflicts of interest: Dr Wan is supported in part by a grant from Pfizer. Dr Winthrop receives grants from Bristol-Myers Squibb and Pfizer and is a consultant for UCB, AbbVie, Lilly, Bristol-Myers Squibb, Pfizer, GlaxoSmithKline, and Roche. Dr Gelfand served as a consultant for Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Janssen Biologics, Novartis Corp, Regeneron, UCB (Data Safety and Monitoring Board), Sanofi, and Pfizer Inc, receiving honoraria; receives research grants (to the Trustees of the University of Pennsylvania) from AbbVie, Janssen, Novartis Corp, Sanofi, Celgene, Ortho Dermatologics, and Pfizer Inc; and has received payment for CME work related to psoriasis that was supported indirectly by Eli Lilly and Company and Ortho Dermatologics. Dr Gelfand is a copatent holder of resiquimod for treatment of cutaneous T-cell lymphoma and is a deputy editor for the Journal of Investigative Dermatology, receiving honoraria from the Society for Investigative Dermatology. Dr Shin has no conflicts of interest to declare. Funding Information: Funding sources: Supported in part by a grant ( P30-AR-069589-03 ) from the National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases to Dr Gelfand.
PY - 2020/12
Y1 - 2020/12
UR - http://www.scopus.com/inward/record.url?scp=85095406786&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85095406786&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2020.07.097
DO - 10.1016/j.jaad.2020.07.097
M3 - Letter
C2 - 32735975
AN - SCOPUS:85095406786
SN - 0190-9622
VL - 83
SP - e445
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 6
ER -